Literature DB >> 31687357

Obstructive azoospermia secondary to bilateral epididymal cystadenomas in a patient with von Hippel-Lindau.

Patrick T Gomella1, Paul Shin2, Ramaprasad Srinivasan1, W Marston Linehan1, Mark W Ball1.   

Abstract

von Hippel-Lindau (VHL) is a heritable cancer syndrome associated with findings in multiple organ systems. Male patients can be affected by epididymal cystadenomas which are benign tumors localized to the epididymis. While benign, these tumors can cause pain and in very rare circumstances can have an effect on fertility especially when present bilaterally. We present a case of a young man with obstructive azoospermia secondary to bilateral cystadenomas, with a focus on his work-up and management.

Entities:  

Keywords:  Epididymal obstruction; Obstructive azoospermia; Sperm retrieval; VHL; von-Hippel Lindau

Year:  2019        PMID: 31687357      PMCID: PMC6819818          DOI: 10.1016/j.eucr.2019.100922

Source DB:  PubMed          Journal:  Urol Case Rep        ISSN: 2214-4420


Introduction

von Hippel-Lindau (VHL) is a heritable cancer syndrome associated with findings in multiple organ systems. Individuals are at risk for developing benign and malignant lesions of the kidneys, adrenals, pancreas, central nervous system, eyes and reproductive organs. Epididymal cystadenomas (EC) are benign lesions that occur in 25–60% of affected men. Given their striking microscopic similarity to metastatic clear cell renal cell carcinoma, if excision is pursued, diagnosis relies on clinical history and immunohistochemical staining (typically CK7-positive and CD10-negative) for accurate histologic interpretation. Typically, epididymal cystadenomas are slow growing painless epidydimal nodules, however some patients report pain with these lesion (approximately 10%) and desire excision. Given the usual benign clinical course of these lesions, they are followed conservatively, unless the patient is symptomatic. While rare, cystadenomas, especially when bilateral, can be a cause of male factor infertility, with only several reported cases in the literature. Details of the previous case reports in the literature are summarized in Table 1. Herein we present an additional case of a patient with azoospermia in the setting of bilateral epididymal cystadenomas with a focus on his work-up and management.
Table 1

Previous Reported Cases of Infertility in setting of Bilateral Epididymal Cystadenomas.

AuthorsJournalPublication YearPatient AgeClinical DetailsManagement
Crisp et al.British Journal of Urology197532Primary InfertilityScrotal Exploration; Vasogram; Epididymal and Testicular Biopsy
Tsuda et al.Cancer197630 & 39Infertility & Scrotal SwellingNot discussed
deSouza Andrade et al.Journal of Urology198529Attempted to concieve for 14 monthsLesion excision followed by Testicular Biopsy
Witten et al.Journal of Urology198524Primary InfertilityTesticular Exploration; no sperm seen on microsurgical dissection of epididymis; Testicular biopsy performed with sperm retrieved
Pozza et al.Urologia Internationalis199428Primary InfertilityScrotal Exploration
Previous Reported Cases of Infertility in setting of Bilateral Epididymal Cystadenomas.

Case details

A 30-year-old male with VHL presented for enrollment in a clinical trial at our institution. Prior to initiation of the trial, he pursued sperm banking to preserve his fertility if the trial effected spermatogenesis. A properly collected semen specimen was analyzed and despite normal volume (2.7 cc), he was found to be azoospermic. An azoospermia work-up was initiated which included a focused physical exam, blood work (testosterone, FSH, LH, karyotype, y chromosome microdeletion analysis) and a scrotal ultrasound. All patients at our institution are enrolled in active research protocols which include acknowledgement of informed consent for the responsible use of the data obtained in the course of their care, additionally no identifiable information is included in this case report. Details of the laboratory evaluation are included in Table 2 and were all within normal limits. On physical exam, he had bilateral painless firm lesions involving the heads of both epididymides consistent with epididymal cystadenomas and testicles with normal texture. Scrotal ultrasound confirmed bilateral lobulated cystic lesion in both epididymides with bilateral dilated rete testes with high normal testicular volumes (23 cc right; 19 cc left). Representative ultrasound images are included in Fig. 1. He was diagnosed with obstructive azoospermia and counseled on his options. He elected sperm retrieval and cryopreservation to allow him to pursue intracytoplasmic sperm injection or in vitro fertilization in the future. Under general anesthesia, he first underwent epididymal aspiration which noted ample fluid with crystals but no sperm. A testicular biopsy was performed with ample sperm recovered which were able to be preserved.
Table 2

Laboratory evaluation.

Lab TestResult
FSH4.9 U/L
LH3.6 U/L
SHBG33 nmol/L (13–71)
Total Testosterone433 ng/dL (262–1593)
Albumin4.6 g/dL (3.5–5.2)
Free Testosterone8.6 ng/dL (7.4–22.6)
KaryotypeNormal
Y Chromosome microdeletionNo deletion identified
Fig. 1

Ultrasound Images. Right and Left Testicles noted dilated rete testes (Arrows-Images A, B); Bilateral epididymal lesions with mostly solid components and small cystic areas consistent with cystadenomas (Arrows-Images C, D).

Laboratory evaluation. Ultrasound Images. Right and Left Testicles noted dilated rete testes (Arrows-Images A, B); Bilateral epididymal lesions with mostly solid components and small cystic areas consistent with cystadenomas (Arrows-Images C, D).

Discussion

It is unclear what percentage of male VHL patients are afflicted with male factor infertility. The focus on family planning in patients with a confirmed pathogenic mutation of the VHL gene focuses mostly on pre-natal testing and pre-implantation genetic diagnosis, which have been used successfully in patients with hereditary cancer syndromes. When comparing VHL patients to unaffected siblings, reproductive ability was only shown to be slightly reduced (8.1 children/100 reproductive years vs 9.79/100 reproductive years) in those effected with VHL. In male VHL patients who are affected with infertility, a high index of suspicion is necessary to evaluate for anatomic obstruction in patients with epididymal cystadenomas. Scrotal ultrasound can be used to follow epididymal cystadenomas in affected individuals and was an important component in the evaluation of azoospermia in this patient. On ultrasound, ECs typically show as an ovoid mass in the head of the epididymis which is mostly solid with some cystic areas. In one series, 23% of VHL patients were found to have dilated rete testes but only in patients age 30 and older. No specific fertility work up was performed in this series; however, several patients with bilateral EC were able to father children naturally. While dilated rete testes are associated with distal obstruction, it does not confirm obstruction and would need to be further investigated with a semen analysis if azoospermia or fertility issues are encountered in a patient with such findings. In a patient with obstructive azoospermia and bilateral epididymal cystadenomas who desires children, the optimal treatment strategy has not been established. Symptomatic ECs are most often treated with epididymectomy, which itself renders the treated side azoospermic. While cyst excision can be performed, as in with spermatocelectomy, epididymal injury can occur and cyst excision is not guaranteed to relieve the obstruction. Standard approaches to obstructive azoospermia which include sperm retrieval via percutaneous or open biopsy of the epididymis and/or testicle or bypass/repair of the obstructed area using microsurgical techniques are the preferred management strategies. While reconstruction may be a viable option in a patient desiring to try and conceive naturally, sperm retrieval for use with assisted reproductive techniques has a near 100% success in this clinical scenario for collection of viable sperm.
  5 in total

1.  The workup and management of azoospermic males.

Authors:  Keith Jarvi; Kirk Lo; Ethan Grober; Victor Mak; Anthony Fischer; John Grantmyre; Armand Zini; Peter Chan; Genevieve Patry; Victor Chow; Trustin Domes
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

2.  Epididymal cystadenomas in von Hippel-Lindau disease.

Authors:  P L Choyke; G M Glenn; J P Wagner; I A Lubensky; K Thakore; B Zbar; W M Linehan; M M Walther
Journal:  Urology       Date:  1997-06       Impact factor: 2.649

Review 3.  Preimplantation genetic diagnosis (PGD) for heritable neoplasia.

Authors:  Joe Leigh Simpson; Sandra A Carson; Pauline Cisneros
Journal:  J Natl Cancer Inst Monogr       Date:  2005

4.  Von Hippel-Lindau disease: a genetic study.

Authors:  E R Maher; L Iselius; J R Yates; M Littler; C Benjamin; R Harris; J Sampson; A Williams; M A Ferguson-Smith; N Morton
Journal:  J Med Genet       Date:  1991-07       Impact factor: 6.318

Review 5.  von Hippel-Lindau disease.

Authors:  Russell R Lonser; Gladys M Glenn; McClellan Walther; Emily Y Chew; Steven K Libutti; W Marston Linehan; Edward H Oldfield
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

  5 in total
  2 in total

1.  Whole-Exome Sequencing Identifies the VHL Mutation (c.262T > C, p.Try88Arg) in Non-Obstructive Azoospermia-Associated Cystic Renal Cell Carcinoma.

Authors:  Yonghong Man; Xuejun Shang; Chunyu Liu; Wei Zhang; Qian Huang; Suheng Ma; Rita Shiang; Feng Zhang; Ling Zhang; Zhibing Zhang
Journal:  Curr Oncol       Date:  2022-03-28       Impact factor: 3.109

2.  Multidisciplinary integrated care pathway for von Hippel-Lindau disease.

Authors:  Wendy P G Wolters; Koen M A Dreijerink; Rachel H Giles; Anouk N A van der Horst-Schrivers; Bernadette van Nesselrooij; Wouter T Zandee; Henri J L M Timmers; Tatjana Seute; Wouter W de Herder; Annemarie A Verrijn Stuart; Emine Kilic; Willem M Brinkman; Patricia J Zondervan; W Peter Vandertop; Anthony B Daniels; Tijmen Wolbers; Thera P Links; Rachel S van Leeuwaarde
Journal:  Cancer       Date:  2022-05-17       Impact factor: 6.921

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.